<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00940771</url>
  </required_header>
  <id_info>
    <org_study_id>PCH 09-004</org_study_id>
    <nct_id>NCT00940771</nct_id>
  </id_info>
  <brief_title>Equivalence of Boosted Atazanavir Based Regimens and Currently Effective HAART Regimens</brief_title>
  <official_title>Equivalence of Boosted Atazanavir Based Regimens and Currently Effective HAART Regimens With Other PI's/NNRTI's in HIV+ Children and Adolescents With Elevated Lipid Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Phoenix Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Phoenix Children's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis for this study is whether a treatment regimen containing Atazanavir in
      combination with Ritonavir will work as well as other regimens containing a protease
      inhibitor and/or a Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) at controlling HIV
      disease in children who are HIV+ and have high cholesterol or high triglycerides. . In this
      study, children who have high cholesterol or high triglycerides as a result of their HIV
      medicines, will have the PI or NNRTI in their medication regimen changed to Atazanavir, which
      is a PI in combination with a low dose of Ritonavir (another PI). Atazanavir has been shown
      in adults to result in lower cholesterol and triglycerides than other PI's and NNRTI's. The
      dose of Atazanavir and Ritonavir will be according to the Package Insert for this drug that
      is FDA approved for children. They will continue taking the other medications from the
      pre-study regimen. Children will take study drug for 24 weeks, and will be able to continue
      study drug after the study using commercially available drug. Lab tests and a physical exam
      will be undertaken at 4 weeks, 12 weeks and 24 weeks after starting study drug to determine
      how effective the new drug is and to monitor for possible side effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to determine if Atazanavir and Ritonavir together will
      be as effective as the child's previous regimen in keeping the level of virus in the blood
      stream at such a low level it can't be found and whether that combination will be as
      effective as the previous regimen in keeping the infection fighting cells in the blood at the
      same level.

      Secondary objectives will be:

        -  To determine if cholesterol and triglyceride levels drop in children switching to
           Atazanavir and Ritonavir from other medication regimens.

        -  To evaluate if Atazanavir and Ritonavir result in an increase in patient satisfaction
           and patient reported adherence and a decrease in symptoms related to medication side
           effects.

      Inclusion Criteria are:

        -  On the same medication regimen at least 3 months

        -  Weight equal to or greater than 25kg

        -  Able to swallow pills or willing to learn

        -  Have a parent or guardian willing and able to sign informed consent

        -  Not be taking a medication which interacts with Atazanavir

        -  Not be currently taking Sustiva
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 26, 2009</start_date>
  <completion_date type="Actual">November 23, 2016</completion_date>
  <primary_completion_date type="Actual">October 16, 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Non-fasting Cholesterol</measure>
    <time_frame>4 Weeks, 12 weeks, 24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-fasting Triglycerides</measure>
    <time_frame>4 weeks, 12 weeks, 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Viral Load</measure>
    <time_frame>4 weeks, 12 weeks, 24 weeks</time_frame>
    <description>Number of participants with undetectable viral load</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 Count</measure>
    <time_frame>4 Weeks, 12 weeks, 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Pediatric HIV</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>boosted Atazanavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Boosted Atazanavir was switched for the PI or NNRTI in the patients regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Boosted Atazanavir</intervention_name>
    <description>Boosted Atazanavir, once a day dose adjusted for child's weight for 6 months.</description>
    <arm_group_label>boosted Atazanavir</arm_group_label>
    <other_name>Reyataz</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV positive children with elevated lipid levels

          -  on stable HAART for at least 3 months (defined to be on the same regimen with viral
             load &lt; 1000 for 6 months prior to baseline visit).

          -  Weight equal to or greater than 25kg

          -  Able to swallow pills or willing to learn

        Exclusion Criteria:

          -  Patients with underlying hepatitis B or C viral infections

          -  Previously demonstrated clinically significant hypersensitivity (eg, Stevens-Johnson
             syndrome, erythema multiforme, or toxic skin eruptions) to any of the components of
             Reyataz® (atazanavir).

          -  Taking other medications that are highly dependent on CYP3A or UGT1A1 for clearance

               -  Ergot medicines: dihydroergotamine, ergonovine, ergotamine, and methylergonovine
                  such as Cafergot®, Migranal®, D.H.E. 45®, ergotrate maleate, Methergine®, and
                  others (used for migraine headaches).

               -  Orap® (pimozide, used for Tourette's disorder).

               -  Propulsid® (cisapride, used for certain stomach problems).

               -  Triazolam, also known as Halcion® (used for insomnia).

               -  Midazolam, also known as Versed® (used for sedation), when taken by mouth.

               -  Camptosar® (irinotecan, used for cancer).

               -  Crixivan® (indinavir, used for HIV infection).

               -  Cholesterol-lowering medicines Mevacor® (lovastatin) or Zocor® (simvastatin).

               -  Rifampin (also known as Rimactane®, Rifadin®, Rifater®, or Rifamate®).

               -  St. John's wort (Hypericum perforatum), an herbal product sold as a dietary
                  supplement,

               -  Viramune® (nevirapine, used for HIV infection).

               -  Vfend® (voriconazole).

          -  Patients with grade 3 or higher elevations in transaminases (&gt; 10 X ULN)

          -  Women of Childbearing Potential who are unwilling or unable to use an acceptable
             method to avoid pregnancy for the entire study period.

          -  Women who are pregnant or breastfeeding.

          -  Women with a positive pregnancy test.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janice Piatt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Phoenix Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 15, 2009</study_first_submitted>
  <study_first_submitted_qc>July 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2009</study_first_posted>
  <results_first_submitted>March 20, 2019</results_first_submitted>
  <results_first_submitted_qc>April 15, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 20, 2020</results_first_posted>
  <last_update_submitted>April 15, 2020</last_update_submitted>
  <last_update_submitted_qc>April 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Phoenix Children's Hospital</investigator_affiliation>
    <investigator_full_name>Janice Piatt</investigator_full_name>
    <investigator_title>Medical Director, Bill Holt Clinic</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Lipids</keyword>
  <keyword>Atazanavir</keyword>
  <keyword>Pediatric</keyword>
  <keyword>treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atazanavir Sulfate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Pediatric patients with elevated cholesterol were recruited from a Pediatric HIV Clinic between April 8, 2009 and May 1, 2013.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Boosted Atazanavir</title>
          <description>Boosted atazanavir was switched for the PI or NNRTI in the patients regimen
Boosted atazanavir, once a day dose adjusted for child's weight for 6 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Pre-Entry</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>4 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>12 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>24 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Boosted Atazanavir</title>
          <description>Boosted atazanavir was switched for the PI or NNRTI in the patients regimen
Boosted Atazanavir: Boosted atazanavir, once a day dose adjusted for child's weight for 6 months.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.5" lower_limit="6" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4</title>
          <units>cells/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1233.1" spread="473.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Viral Load</title>
          <units>copies/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.3" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cholesterol</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="214.3" spread="31.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglycerides</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="288.5" spread="253.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Non-fasting Cholesterol</title>
        <time_frame>4 Weeks, 12 weeks, 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Boosted Atazanavir</title>
            <description>Boosted atazanavir was switched for the PI or NNRTI in the patients regimen
Boosted atazanavir, once a day dose adjusted for child's weight for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Non-fasting Cholesterol</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="187.2" spread="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178.5" spread="38.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181.5" spread="29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Friedman's Test</non_inferiority_desc>
            <p_value>.006</p_value>
            <method>Friedman's Test</method>
            <method_desc>3 degrees of freedom.</method_desc>
            <param_type>Chi Square</param_type>
            <param_value>12.3</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Nul lHypothesis that there is no difference between specific time points.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Post Hoc testing Post hoc Wilcoxon Signed Rank tests</non_inferiority_desc>
            <p_value>.007</p_value>
            <method>Wilcoxon Signed Rank</method>
            <method_desc>Z=-2.701</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Non-fasting Triglycerides</title>
        <time_frame>4 weeks, 12 weeks, 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Boosted Atazanavir</title>
            <description>Boosted atazanavir was switched for the PI or NNRTI in the patients regimen
Boosted atazanavir, once a day dose adjusted for child's weight for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Non-fasting Triglycerides</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="240.5" spread="107.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195.5" spread="93.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193.3" spread="106.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Friedman's test with 3 df</non_inferiority_desc>
            <p_value>.356</p_value>
            <method>Friedman's Test</method>
            <method_desc>3 degrees of freedom</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Viral Load</title>
        <description>Number of participants with undetectable viral load</description>
        <time_frame>4 weeks, 12 weeks, 24 weeks</time_frame>
        <population>Number of patients with undetectable viral load</population>
        <group_list>
          <group group_id="O1">
            <title>Boosted Atazanavir</title>
            <description>Boosted atazanavir was switched for the PI or NNRTI in the patients regimen
Boosted atazanavir, once a day dose adjusted for child's weight for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Load</title>
          <description>Number of participants with undetectable viral load</description>
          <population>Number of patients with undetectable viral load</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was a difference. We were looking for no difference between before and after switch.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.801</p_value>
            <method>Friedman's test</method>
            <method_desc>3 degrees of freedom</method_desc>
            <param_type>Chi-square</param_type>
            <param_value>1.0</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>1.0 is the actual calculated Chi-X value, not the p value.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD4 Count</title>
        <time_frame>4 Weeks, 12 weeks, 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Boosted Atazanavir</title>
            <description>Boosted atazanavir was switched for the PI or NNRTI in the patients regimen
Boosted atazanavir, once a day dose adjusted for child's weight for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>CD4 Count</title>
          <units>cells/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1214.3" spread="476.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1151.9" spread="442.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1120.0" spread="413.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Friedman's test</non_inferiority_desc>
            <p_value>.075</p_value>
            <p_value_desc>a priori threshold for statistical significance 0.05</p_value_desc>
            <method>Friedman's test</method>
            <method_desc>3 degrees of freedom</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 weeks</time_frame>
      <desc>The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events V 1.0, December 2004, Clarification August 2009 was used to grade labs and symptoms that were reported at week 4, week 12 and week 24 visits.</desc>
      <group_list>
        <group group_id="E1">
          <title>Boosted Atazanavir</title>
          <description>Boosted atazanavir was switched for the PI or NNRTI in the patients regimen
Boosted atazanavir, once a day dose adjusted for child's weight for 6 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Division of AIDS 1.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pansinusitis</sub_title>
                <description>Pansinusitis requiring hospitalization</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Division of AIDS 1.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Pain, neck and face</sub_title>
                <description>Pain grade 2 associated with parotitis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Grade 3 vomiting associated with parotitis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Laboratory Abnormality</sub_title>
                <description>Elevated Bilirubin, grade 3</description>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <description>Fever grade 2 associated with Parotitis or Upper Respiratory Infection</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pain, throat</sub_title>
                <description>pain grade 2 associated with Upper Respiratory Infection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <description>Cough grade 2 associated with Upper Respiratory Infection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size Non fasting lipid levels Large variety of prior treatment regimens</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Janice Piatt, MD, Medical Director</name_or_title>
      <organization>Bill Holt Clinic, Phoenix Children's Hospital</organization>
      <phone>602-933-0955</phone>
      <email>jpiatt@phoenixchildrens.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

